218 related articles for article (PubMed ID: 22551397)
21. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
[TBL] [Abstract][Full Text] [Related]
22. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Ishihara H; Yagisawa T; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
Int J Clin Oncol; 2017 Feb; 22(1):126-135. PubMed ID: 27549785
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of basal 18F-FDG PET / CT maximum standardized uptake value in patients with metastatic renal cell carcinoma who were treated with sunitinib.
Aytekin A; Aldemir MN; Sakin A; Telci U; Esen R
J BUON; 2020; 25(5):2490-2495. PubMed ID: 33277873
[TBL] [Abstract][Full Text] [Related]
24. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
25. FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.
Nakaigawa N; Kondo K; Tateishi U; Minamimoto R; Kaneta T; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Kubota Y; Inoue T; Yao M
BMC Cancer; 2016 Feb; 16():67. PubMed ID: 26857818
[TBL] [Abstract][Full Text] [Related]
26. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
Riesenbeck LM; Bierer S; Hoffmeister I; Köpke T; Papavassilis P; Hertle L; Thielen B; Herrmann E
World J Urol; 2011 Dec; 29(6):807-13. PubMed ID: 21153827
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
Buchler T; Klapka R; Melichar B; Brabec P; Dusek L; Vyzula R; Abrahamova J
Ann Oncol; 2012 Feb; 23(2):395-401. PubMed ID: 21536664
[TBL] [Abstract][Full Text] [Related]
28. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
Bourlon MT; Gao D; Trigero S; Clemons JE; Breaker K; Lam ET; Flaig TW
Cancer Med; 2016 Dec; 5(12):3386-3393. PubMed ID: 27758076
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
[TBL] [Abstract][Full Text] [Related]
31. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.
Schmitt RJ; Kreidler SM; Glueck DH; Amaria RN; Gonzalez R; Lewis K; Bagrosky BM; Kwak JJ; Koo PJ
Nucl Med Commun; 2016 Feb; 37(2):122-8. PubMed ID: 26440571
[TBL] [Abstract][Full Text] [Related]
32. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
34. FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma.
Pankowska V; Malkowski B; Wedrowski M; Wedrowska E; Roszkowski K
Clin Exp Med; 2019 Feb; 19(1):143-148. PubMed ID: 30488140
[TBL] [Abstract][Full Text] [Related]
35. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
Verma J; Jonasch E; Allen P; Tannir N; Mahajan A
Cancer; 2011 Nov; 117(21):4958-65. PubMed ID: 21484781
[TBL] [Abstract][Full Text] [Related]
36. Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
Herrmann E; Gerss J; Bierer S; Köpke T; Bolenz C; Hertle L; Wülfing C
J Cancer Res Clin Oncol; 2009 Jan; 135(1):61-7. PubMed ID: 18592270
[TBL] [Abstract][Full Text] [Related]
37. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
38. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; Molinié V; Escudier B
Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
[TBL] [Abstract][Full Text] [Related]
39. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Yasuda Y; Saito K; Yuasa T; Uehara S; Kawamura N; Yokoyama M; Ishioka J; Matsuoka Y; Yamamoto S; Okuno T; Yonese J; Kihara K; Fujii Y
Int J Clin Oncol; 2017 Dec; 22(6):1081-1086. PubMed ID: 28733795
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
